Vivani Medical VANI Biopharm Division — D&A

Other segment segments

Similar metrics at other companies

AMP

AMPHPharmaceutical Products — D&A

$14.35M+5.4%

PFEBiopharma — D&A

$348M+5.1%

OPKPharmaceutical — D&A

$18.26M+2.7%

AVT

AVTRBioscience & Medtech Products — D&A

$49.2M+12.3%

VAT

VATELife Sciences — D&A

$100K0.0%

ASSTMedical Device — D&A

$32K—

Questions, answered.

What is Vivani Medical's biopharm division — D&A?

Vivani Medical (VANI) reported biopharm division — D&A of $130K in Q1 2026.

How has Vivani Medical's biopharm division — D&A changed year-over-year?

Vivani Medical's biopharm division — D&A increased by 31.3% year-over-year, from $99K to $130K.

What is the long-term trend for Vivani Medical's biopharm division — D&A?

Over 2 years (2023 to 2025), Vivani Medical's biopharm division — D&A has grown at a 15.6% compound annual growth rate (CAGR), from $307K to $410K.

What does biopharm division — D&A mean?

Represents the non-cash allocation of the cost of tangible and intangible assets over their useful lives within the biopharmaceutical segment. This metric reflects the consumption of the segment's capital base, such as laboratory equipment or patent portfolios. It is essential for understanding the true economic cost of maintaining the segment's operational infrastructure.